Browse by author
Lookup NU author(s): Dr Ross Maxwell
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose: Tumor hypoxia is associated with poor prognosis and a more malignant tumor phenotype. SR-4554, a fluorinated 2-nitroimidazole, is selectively bioreduced and bound in hypoxic cells. We present validation studies of SR-4554 as a noninvasive hypoxia marker detected by fluorine-19 magnetic resonance spectroscopy (19F MRS) in the P22 carcinosarcoma, a tumor with clinically relevant hypoxia levels. Experimental Design: Tumor-bearing female severe combined immunodeficient mice received SR-4554 at 180 mg/kg. Pharmacokinetic studies of parent SR-4554 in plasma and tumors were performed using high-performance liquid chromatography-UV. Total SR-4554 (parent SR-4554 and bioreduction products) was monitored in tumor by 19F MRS using a 4.7 T spectrometer, with continuous acquisition for up to 5 h. A parameter of total SR-4554 retention, the 3-h 19F retention index (19FRI) was determined. Tumor pO2, assessed polarographically, was decreased (5 mg/kg hydralazine or 100 mg/kg combretastatin A-4 phosphate) or increased [1 l/min carbogen (5% CO2, 95% O2) plus 500 mg/kg nicotinamide], and the corresponding 19FRI was measured. Results: Comparative HPLC-UV- and MRS-derived assessments of parent and total SR-4554, respectively, indicated that concentrations of total SR-4554 consistently exceeded parent SR-4554, the differential increasing with time. This indicates formation and retention of SR-4554 bioreduction products in tumor, confirming the presence of hypoxia. The 19FRI was higher in hydralazine- and combretastatintreated animals compared with unmodulated animals (P 0.004 and 0.15, respectively) and animals receiving carbogen and nicotinamide (P 0.0001 and 0.005, respectively). Significant correlations were demonstrated between mean 19FRI and polarographic pO2 parameters (P < 0.002). Conclusions: Retention of hypoxia-related SR-4554 bioreduction products can be detected in the clinically relevant P22 tumor by 19F MRS, and the 19FRI correlates with polarographically measured pO2. These findings support the use of SR 4554 as a noninvasive hypoxia marker.
Author(s): Seddon BM, Maxwell RJ , Grimshaw R, Raynaud F, Tozer GM, Workman P, Honess DJ
Publication type: Article
Publication status: Published
Journal: Clinical Cancer Research
Year: 2002
Volume: 8
Issue: 7
Pages: 2323-2335
ISSN (print): 1078-0432
ISSN (electronic): 1557-3265
Publisher: American Association for Cancer Research
URL: http://clincancerres.aacrjournals.org/cgi/reprint/8/7/2323
Notes: RJM proposed and supervised animal magnetic resonance study based on earlier work with PW on another potential hypoxia marker. Study supports clinical research with this marker using magnetic resonance techniques.
